A method and a system for producing a change in a medium disposed in an artificial container. The method places inavicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

The present invention relates to an apparatus (1) for use in irradiation therapy, comprising an ionization module (2) adapted to emit ionization irradiation, and a power source (4) and a control unit (5) to provide a user interface. The apparatus is characterized in that the apparatus comprises an UV module (3) adapted to emit UVA, UVB and/or UVC irradiation (9), whereby the ionization module and the UV module emit irradiation simultaneously or alternately, and the ionization module emits irradiation (8) at a wave length at least below 100 nm. The invention also relates to a use of the apparatus for radiating an object (7) and use of the apparatus and method for treatment of a mammal (7). A detector may measure and/or create an image of the irradiation (6).

Products, compositions, systems, and methods for treating a subject carrying a virus or bacterium. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to the subject thus producing an effect on or change to a target structure of the subject directly or indirectly. The methods may further be performed by application of an initiation energy to a subject to activate within the subject a photoactivatable drug directly or indirectly, optionally in the presence of one or more plasmonics active agents, thus treating the virus or bacterium. Also provided are kits containing products or compositions formulated or configured and systems for use in practicing these methods.

Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

A kit for use in performing a cancer treatment, having a vial containing a phosphor-containing drug activator, wherein the phosphor-containing drug activator is present in the vial at a dosage level that is correlated with a size of tumor to be treated, and a container containing the vial; wherein the phosphor-containing drug activator contains an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; where the two or more phosphors include Zn.sub.2SiO.sub.4:Mn.sup.2+ and (3Ca.sub.3(PO.sub.4).sub.2Ca(F, Cl).sub.2:Sb.sup.3+, Mn.sup.2+) at a ratio (Zn.sub.2SiO.sub.4:Mn.sup.2+):(3Ca.sub.3(PO.sub.4).sub.2Ca(F, Cl).sub.2:Sb.sup.3+, Mn.sup.2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating and a diamond-like carbon coating.